Effectiveness and clinical predictors of response to combined ECT and antipsychotic therapy in patients with treatment-resistant schizophrenia and dominant negative symptoms

Psychiatry Research

Volumn 220, Issue 1-2, 2014, Pages 175-180

  Pawełczyk, Tomasz ^a   Kołodziej Kowalska, Emilia ^a   Pawełczyk, Agnieszka ^a   Rabe Jabłońska, Jolanta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Antipsychotics; Electroconvulsive therapy; Schizophrenia; Treatment resistance

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; ELECTROCONVULSIVE THERAPY UNIT; FEMALE; HUMAN; MALE; MONOTHERAPY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; TREATMENT RESISTANT SCHIZOPHRENIA; TREATMENT RESPONSE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908240429     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.07.071     Document Type: Article

References (40)

1. Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition 2004, American Psychiatric Association, American Psychiatric Association, Washington, DC.
2. Benatov R., Sirota P., Megged S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convulsive Therapy 1996, 12(2):117-121.
3. Bhatia S.C., Bhatia S.K., Gupta S. Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia. The Journal of ECT 1998, 14(4):280-283.
4. Biedermann F., Pfaffenberger N., Baumgartner S., Kemmler G., Fleischhacker W.W., Hofer A. Combined clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia: clinical and cognitive outcomes. The Journal of ECT 2011, 27(4):e61-e62. 10.1097/YCT.0b013e31821a8f05.
5. Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. The American Journal of Psychiatry 1998, 155(4):499-504.
6. Braga R.J., Petrides G. The combined use of electroconvulsive therapy and antipsychotics in patients with schizophrenia. The Journal of ECT 2005, 21(2):75-83.
7. Brenner H.D., Dencker S.J., Goldstein M.J., Hubbard J.W., Keegan D.L., Kruger G., Kulhanek F., Liberman R.P., Malm U., Midha K.K. Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin 1990, 16(4):551-561.
8. Chanpattana W., Andrade C. ECT for treatment-resistant schizophrenia: a response from the far East to the UK. NICE report. The Journal of ECT 2006, 22(1):4-12.
9. Chanpattana W., Chakrabhand M.L., Kongsakon R., Techakasem P., Buppanharun W. Short-term effect of combined ECT and neuroleptic therapy in treatment-resistant schizophrenia. The Journal of ECT 1999, 15(2):129-139.
10. Chanpattana W., Chakrabhand M.L., Sackeim H.A., Kitaroonchai W., Kongsakon R., Techakasem P., Buppanharun W., Tuntirungsee Y., Kirdcharoen N. Continuation ECT in treatment-resistant schizophrenia: a controlled study. The Journal of ECT 1999, 15(3):178-192.
11. Chanpattana W., Chakrabhand M.L. Combined ECT and neuroleptic therapy in treatment-refractory schizophrenia: prediction of outcome. Psychiatry Research 2001, 105(1-2):107-115.
12. Chanpattana W., Kramer B.A. Acute and maintenance ECT with flupenthixol in refractory schizophrenia: sustained improvements in psychopathology, quality of life, and social outcomes. Schizophrenia Research 2003, 63(1-2):189-193.
13. Chanpattana W., Sackeim H.A. Electroconvulsive therapy in treatment-resistant schizophrenia: prediction of response and the nature of symptomatic improvement. The Journal of ECT 2010, 26(4):289-298. 10.1097/YCT.0b013e3181cb5e0f.
14. Fink M., Sackeim H.A. Convulsive therapy in schizophrenia?. Schizophrenia Bulletin 1996, 22(1):27-39.
15. Havaki-Kontaxaki B.J., Ferentinos P.P., Kontaxakis V.P., Paplos K.G., Soldatos C.R. Concurrent administration of clozapine and electroconvulsive therapy in clozapine-resistant schizophrenia. Clin Neuropharmacol 2006, 29(1):52-56.
16. James D.V., Gray N.S. Elective combined electroconvulsive and clozapine therapy. International Clinical Psychopharmacology 1999, 14(2):69-72.
17. Kales H.C., Dequardo J.R., Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Progress in Neuro-psychopharmacology &. Biological Psychiatry 1999, 23(3):547-556.
18. Kho K.H., Blansjaar B.A., Vries S., de, Babuskova D., Zwinderman A.H., Linszen D.H. Electroconvulsive therapy for the treatment of clozapine nonresponders suffering from schizophrenia--an open label study. European Archives of Psychiatry and Clinical Neuroscience 2004, 254(6):372-379. 10.1007/s00406-004-0517-y.
19. Koehler K., Sauer H. First rank symptoms as predictors of ECT response in schizophrenia. The British Journal of Psychiatry: The Journal of Mental Science 1983, 142:280-283.
20. Kristensen D., Hageman I., Bauer J., Jorgensen M.B., Correll C.U. Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy. The Journal of ECT 2013, 29(4):271-276. 10.1097/YCT.0b013e31828b34f6.
21. Landmark J., Joseph L., Merskey H. Characteristics of schizophrenic patients and the outcome of fluphenazine and of electroconvulsive treatments. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1987, 32(6):425-428.
22. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology 2007, 32(9):1903-1910. 10.1038/sj.npp.1301325.
23. Masdrakis V.G., Florakis A., Tzanoulinos G., Markatou M., Oulis P. Safety of the electroconvulsive therapy-ziprasidone combination. The Journal of ECT 2010, 26(2):139-142. 10.1097/YCT.0b013e3181c1880e.
24. Masdrakis V.G., Oulis P., Zervas I.M., Karakatsanis N.A., Kouzoupis A.V., Karapoulios E., Soldatos C.R. The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. The Journal of ECT 2008, 24(3):236-238. 10.1097/YCT.0b013e3181571c0e.
25. Masdrakis V.G., Oulis P., Zervas I.M., Karakatsanis N.A., Kouzoupis A.V., Karapoulios E., Soldatos C.R. The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. The Journal of ECT 2008, 24(3):236-238. 10.1097/YCT.0b013e3181571c0e.
26. Masoudzadeh A., Khalilian A.R. Comparative study of clozapine, electroshock and the combination of ECT with clozapine in treatment-resistant schizophrenic patients. Pakistan journal of Biological Sciences: PJBS 2007, 10(23):4287-4290.
27. Meltzer H.Y. Treatment-resistant schizophrenia-the role of clozapine. Current Medical Research and Oopinion 1997, 14(1):1-20. 10.1185/03007999709113338.
28. NICE, 2003. National Institute for Clinical Excellence (Great Britain), National Collaborating Centre for Mental Health (Great Britain): Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. Gaskell and the British Psychological Society.
29. Nothdurfter C., Eser D., Schule C., Zwanzger P., Marcuse A., Noack I., Moller H.J., Rupprecht R., Baghai T.C. The influence of concomitant neuroleptic medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy. The World Journal of Biological Psychiatry: The Official Journal of The World Federation of Societies of Biological Psychiatry 2006, 7(3):162-170. 10.1080/15622970500395280.
30. Painuly N., Chakrabarti S. Combined use of electroconvulsive therapy and antipsychotics in schizophrenia: the Indian evidence. A review and a meta-analysis. The Journal of ECT 2006, 22(1):59-66.
31. Peuskens J. The evolving definition of treatment resistance. The Journal of Clinical Psychiatry 1999, 60(Suppl 12):S4-S8.
32. Porcelli S., Balzarro B., Serretti A. Clozapine resistance: augmentation strategies. European Neuropsychopharmacology: The journal of the European College of Neuropsychopharmacology 2012, 22(3):165-182. 10.1016/j.euroneuro.2011.08.005.
33. Ravanic D.B., Pantovic M.M., Milovanovic D.R., Dukic-Dejanovic S., Janjic V., Ignjatovic D.R., Jovic S.D., Jurisic V., Jevtovic I. Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. Psychiatria Danubina 2009, 21(2):179-186.
34. Safferman A.Z., Munne R. Combining Clozapine with ECT. Convulsive Therapy 1992, 8(2):141-143.
35. Sajatovic M., Meltzer H.Y. The Effect of Short-Term Electroconvulsive Treatment Plus Neuroleptics in Treatment-Resistant Schizophrenia and Schizoaffective Disorder. Convulsive Therapy 1993, 9(3):167-175.
36. Takacs R., Ivanyi Z., Ungvari G.S., Gazdag G. Safety of the electroconvulsive therapy and amisulpride combination. Psychiatria Danubina 2013, 25(1):76-79.
37. Tang W.K., Ungvari G.S. Electroconvulsive therapy in rehabilitation: the Hong Kong experience. Psychiatric Services 2001, 52(3):303-306.
38. Tang W.K., Ungvari G.S. Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial. The Journal of ECT 2002, 18(2):90-94.
39. Tang W.K., Ungvari G.S. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial. Progress in Neuro-psychopharmacology & Biological Psychiatry 2003, 27(3):373-379. 10.1016/S0278-5846(02)00354-8.
40. Weiner R. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging: A Task Force report of the American Psychiatric Association 2001, American Psychiatric Association, Washington, DC.